Literature DB >> 28621002

Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.

T H Wong1, S Sinclair1, B Smith1, C Fraser1, C A Morton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28621002     DOI： 10.1111/ced.13150

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  4 in total

1.  Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.

Authors:  Abhishek De; Sudip Das; Dhiraj Dhoot; Aarti Sarda
Journal:  Indian J Dermatol       Date:  2020 Sep-Oct       Impact factor: 1.494

2.  Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.

Authors:  Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf
Journal:  JAAD Int       Date:  2020-12-26

3.  Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.

Authors:  Bela J Shah; Deval Mistry; Navin Chaudhary; Shikha Shah
Journal:  Indian Dermatol Online J       Date:  2020-01-13

4.  Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.

Authors:  Daniele Melis; Cristina Mugheddu; Silvia Sanna; Laura Atzori; Franco Rongioletti
Journal:  Dermatol Ther       Date:  2020-06-24       Impact factor: 3.858
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.